Melda Sarıman
Research Subjects
Melda Sarıman has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Neslihan Abacı
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
3 shared publications - Sema Sırma Ekmekci
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
3 shared publications - Burcu Salman Yaylaz
Istanbul Universitesi
2 shared publications - Ferda Perçin Paçal
Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
2 shared publications - Zeliha Emrence
Department of Genetics, Istanbul University, Aziz Sancar Institute of Experimental Medicine , Istanbul
2 shared publications - Ahmet Emre Eşkazan
Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 3 March 2026
- Published by Harran Universitesi Tip Fakultesi Dergisi in Harran Üniversitesi Tıp Fakültesi Dergisi
- Vol. 23 (1) , 14-20
Modulation of TGF-Β Signaling to Enhance Irinotecan Cytotoxicity in Colorectal Cancer
Background: Impaired Transforming Growth Factor Beta (TGF-β) signaling contributes to colorectal cancer (CRC) progression. Targeting TGF-β receptors (TGFβR) in combination with established chemotherapies may enhance treatment efficacy. This study investigates the effects of a TGFβR-I/II inhibitor (LY2109761) on the cytotoxic activity of irinotecan in the human colorectal cancer cell line HCT-116.Materials and Methods: LY2109761 was used to pharmacologically inhibit TGFβR-I/II in HCT-116 cells. Cell viability following treatment with irinotecan, LY2109761, or their combination was assessed using the MTT assay. Real-time quantitative polymerase chain reaction (RT-qPCR) quantified mRNA levels of genes associated with cell death, cell cycle, and TGF-β signaling.Results: Combination therapy of LY2109761 and irinotecan significantly reduced cell viability in HCT-116 cells in a dose- and time-dependent manner. Enhanced expression of cell cycle inhibitor P21 and increased markers of apoptosis and autophagy were observed.Conclusions: The combination of LY2109761 and irinotecan exhibited enhanced cytotoxicity compared to irinotecan alone, suggesting this approach as a promising therapeutic strategy for CRC.
- 3 March 2026
- Published by Harran Universitesi Tip Fakultesi Dergisi in Harran Üniversitesi Tıp Fakültesi Dergisi
- Vol. 23 (1) , 14-20
Open AccessModulation of TGF-Β Signaling to Enhance Irinotecan Cytotoxicity in Colorectal Cancer
Background: Impaired Transforming Growth Factor Beta (TGF-β) signaling contributes to colorectal cancer (CRC) progression. Targeting TGF-β receptors (TGFβR) in combination with established chemotherapies may enhance treatment efficacy. This study investigates the effects of a TGFβR-I/II inhibitor (LY2109761) on the cytotoxic activity of irinotecan in the human colorectal cancer cell line HCT-116.Materials and Methods: LY2109761 was used to pharmacologically inhibit TGFβR-I/II in HCT-116 cells. Cell viability following treatment with irinotecan, LY2109761, or their combination was assessed using the MTT assay. Real-time quantitative polymerase chain reaction (RT-qPCR) quantified mRNA levels of genes associated with cell death, cell cycle, and TGF-β signaling.Results: Combination therapy of LY2109761 and irinotecan significantly reduced cell viability in HCT-116 cells in a dose- and time-dependent manner. Enhanced expression of cell cycle inhibitor P21 and increased markers of apoptosis and autophagy were observed.Conclusions: The combination of LY2109761 and irinotecan exhibited enhanced cytotoxicity compared to irinotecan alone, suggesting this approach as a promising therapeutic strategy for CRC.
- Open Access
- 9 February 2023
- Published by Walter de Gruyter GmbH in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Vol. 4 (1) , 98-104
Elevación de SPINK2 en leucemia mieloide aguda
Resumen: Objectivos: La leucemia mieloide aguda (AML, por sus siglas en inglés) es una enfermedad muy heterogénea. Aunque se puede clasificar a los pacientes en grupos de riesgo según sus mutaciones genéticas, el pronóstico dentro de cada categoría varía sustancialmente. Es perentorio identificar nuevos marcadores moleculares de la AML. Recientemente, se ha descrito la elevación del inhibidor de la serina peptidasa Kazal tipo 2 (SPINK2) en la AML, habiendo sido relacionada con peores resultados clínicos en metaanálisis, así como en un número limitado de pacientes con AML. Métodos: Analizamos la expresión de SPINK2 en 62 pacientes (45 adultos y 17 niños) con AML y en 11 líneas celulares mediante PCR cuantitativa (qRT-PCR). Los niveles de la proteína SPINK2 se determinaron en líneas celulares mediante ELISA. Resultados: Observamos un aumento de expresión del ARNm de SPINK2 y de los niveles de la proteína en las líneas celulares de AML (HL60 y NB4), frente a otras líneas celulares (K562, Jurkat y NALM6, MCF7, HeLa, HUVEC, hFOB, 293T, U87). Los pacientes con AML mostraron una expresión elevada de ARNm de SPINK2 frente a los controles (p=0,004) y esta fue significativamente menor en los pacientes t(8;21) positivos, frente a los pacientes negativos (p=0,0006). Conclusions: Estos resultados sugieren que el gen SPINK2 tiene un papel relevante en el desarrollo de la AML. Son necesarios más estudios para evaluar la expresión de SPINK2 en los pacientes con AML con la mutación t(8.21) e investigar su valor pronóstico en varios subgrupos de pacientes con AML.
- 9 February 2023
- Published by Walter de Gruyter GmbH in Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Vol. 4 (1) , 98-104
Open AccessElevación de SPINK2 en leucemia mieloide aguda
Resumen: Objectivos: La leucemia mieloide aguda (AML, por sus siglas en inglés) es una enfermedad muy heterogénea. Aunque se puede clasificar a los pacientes en grupos de riesgo según sus mutaciones genéticas, el pronóstico dentro de cada categoría varía sustancialmente. Es perentorio identificar nuevos marcadores moleculares de la AML. Recientemente, se ha descrito la elevación del inhibidor de la serina peptidasa Kazal tipo 2 (SPINK2) en la AML, habiendo sido relacionada con peores resultados clínicos en metaanálisis, así como en un número limitado de pacientes con AML. Métodos: Analizamos la expresión de SPINK2 en 62 pacientes (45 adultos y 17 niños) con AML y en 11 líneas celulares mediante PCR cuantitativa (qRT-PCR). Los niveles de la proteína SPINK2 se determinaron en líneas celulares mediante ELISA. Resultados: Observamos un aumento de expresión del ARNm de SPINK2 y de los niveles de la proteína en las líneas celulares de AML (HL60 y NB4), frente a otras líneas celulares (K562, Jurkat y NALM6, MCF7, HeLa, HUVEC, hFOB, 293T, U87). Los pacientes con AML mostraron una expresión elevada de ARNm de SPINK2 frente a los controles (p=0,004) y esta fue significativamente menor en los pacientes t(8;21) positivos, frente a los pacientes negativos (p=0,0006). Conclusions: Estos resultados sugieren que el gen SPINK2 tiene un papel relevante en el desarrollo de la AML. Son necesarios más estudios para evaluar la expresión de SPINK2 en los pacientes con AML con la mutación t(8.21) e investigar su valor pronóstico en varios subgrupos de pacientes con AML.
- Open Access
- 19 November 2020
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 37 (4) , 226-233
LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease resulting from the accumulation of genetic changes that affect the development of T-cells. The precise role of lymphoid enhancer-binding factor 1 (LEF1) in T-ALL has been controversial since both overexpression and inactivating LEF1 mutations have been reported to date. Here, we investigate the potential gene targets of LEF1 in the Jurkat human T-cell leukemia cell line. We used small interfering RNA (siRNA) technology to knock down LEF1 in Jurkat cells and then compared the gene expression levels in the LEF1 knockdown cells with nontargeting siRNA-transfected and non-transfected cells by employing microarray analysis. We identified DHRS2, a tumor suppressor gene, as the most significantly downregulated gene in LEF1 knockdown cells, and we further confirmed its downregulation by real-time quantitative polymerase chain reaction (qRT-PCR) in mRNA and at protein level by western blotting. Our results revealed that DHRS2 is positively regulated by LEF1 in Jurkat cells, which indicates the capability of LEF1 as a tumor suppressor and, together with previous reports, suggests that LEF1 exhibits a regulatory role in T-ALL via not only its oncogenic targets but also tumor suppressor genes.
- 19 November 2020
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 37 (4) , 226-233
Open AccessLEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease resulting from the accumulation of genetic changes that affect the development of T-cells. The precise role of lymphoid enhancer-binding factor 1 (LEF1) in T-ALL has been controversial since both overexpression and inactivating LEF1 mutations have been reported to date. Here, we investigate the potential gene targets of LEF1 in the Jurkat human T-cell leukemia cell line. We used small interfering RNA (siRNA) technology to knock down LEF1 in Jurkat cells and then compared the gene expression levels in the LEF1 knockdown cells with nontargeting siRNA-transfected and non-transfected cells by employing microarray analysis. We identified DHRS2, a tumor suppressor gene, as the most significantly downregulated gene in LEF1 knockdown cells, and we further confirmed its downregulation by real-time quantitative polymerase chain reaction (qRT-PCR) in mRNA and at protein level by western blotting. Our results revealed that DHRS2 is positively regulated by LEF1 in Jurkat cells, which indicates the capability of LEF1 as a tumor suppressor and, together with previous reports, suggests that LEF1 exhibits a regulatory role in T-ALL via not only its oncogenic targets but also tumor suppressor genes.
- Open Access
- 10 January 2019
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 36 (1) , 23-31
Investigation of Gene Expressions of Myeloma Cells in the Bone Marrow of Multiple Myeloma Patients by Transcriptome Analysis
Background: Multiple Myeloma (MM) is plasma cell dyscrasia characterized by transformation of B cells into malignant cells. Although there are data regarding molecular pathology of multiple myeloma, molecularmechanisms of the disease has not been fully explained. Aims: To investigate gene expression profiles in bone marrow myeloma cells via RNA sequencing technology. Study Design: Cell study. Methods: Four untreated MM patients myeloma cells and 4 healthy donors B cells from bone marrow were sorted using FACSAria II. It was occurred two groups as patient pool from myeloma cells and the control pool from B cells. Transcriptome analysis was performed and results were analyzed using bioinformatic tools. Results: Total result of transcriptome data 18.806 transcripts (94.4%) were in pooled MM patients. 992 regions were detected as new exon candidates or altenative splicing regions. In addition, 490 mutations (deletion or insertion) and 1397 SNV were, 415 fusion transcripts, 132 frameshift mutations and 983 fusions which were reported before in NCBI were detected with unknown function were identified in patients. 35.268 transcripts were obtained (71%) (25.355 transcripts were defined previously) in the control pool. This preliminary study, the first 50 genes analyzed with a gene set enchriment analysis program by MSigDB, Enrichr and Panther.Molecular functions, cellular component, pathway and biological process of the genes obtained statistical values by means of bioinformatics tools were presented as supplemental file. Conclusion: EEF1G, ITM2C, FTL, CLPTM1L, and CYBA possible candidate genes were identified in this study which may be associated with myelomagenesis.
- 10 January 2019
- Published by AVES YAYINCILIK A.Ş. in Balkan Medical Journal
- Vol. 36 (1) , 23-31
Open AccessInvestigation of Gene Expressions of Myeloma Cells in the Bone Marrow of Multiple Myeloma Patients by Transcriptome Analysis
Background: Multiple Myeloma (MM) is plasma cell dyscrasia characterized by transformation of B cells into malignant cells. Although there are data regarding molecular pathology of multiple myeloma, molecularmechanisms of the disease has not been fully explained. Aims: To investigate gene expression profiles in bone marrow myeloma cells via RNA sequencing technology. Study Design: Cell study. Methods: Four untreated MM patients myeloma cells and 4 healthy donors B cells from bone marrow were sorted using FACSAria II. It was occurred two groups as patient pool from myeloma cells and the control pool from B cells. Transcriptome analysis was performed and results were analyzed using bioinformatic tools. Results: Total result of transcriptome data 18.806 transcripts (94.4%) were in pooled MM patients. 992 regions were detected as new exon candidates or altenative splicing regions. In addition, 490 mutations (deletion or insertion) and 1397 SNV were, 415 fusion transcripts, 132 frameshift mutations and 983 fusions which were reported before in NCBI were detected with unknown function were identified in patients. 35.268 transcripts were obtained (71%) (25.355 transcripts were defined previously) in the control pool. This preliminary study, the first 50 genes analyzed with a gene set enchriment analysis program by MSigDB, Enrichr and Panther.Molecular functions, cellular component, pathway and biological process of the genes obtained statistical values by means of bioinformatics tools were presented as supplemental file. Conclusion: EEF1G, ITM2C, FTL, CLPTM1L, and CYBA possible candidate genes were identified in this study which may be associated with myelomagenesis.